NVL-655 is under clinical development by Nuvalent and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NVL-655’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NVL-655 overview
NVL-655 is under development for the treatment of solid tumor, non-small cell lung cancer (NSCLC), cholangiocarcinoma, neuroblastoma, anaplastic large cell lymphoma, diffuse large b-cell lymphoma, esophageal squamous cell carcinoma, renal cell carcinoma, breast cancer, inflammatory myofibroblastic tumor (IMT), colorectal cancer, ovarian cancer, papillary thyroid cancer, soft-tissue sarcoma, spitzoid tumor. It is administered through oral route in the form of film-coated tablets. The drug candidate acts by targeting anaplastic lymphoma kinase (ALK).
Nuvalent overview
Nuvalent is a clinical-stage biopharmaceutical company that develops innovative small molecules for cancer. The company’s pipeline products include zidesamtinib (NVL-520) a ROS1-selective inhibitor; NVL-655 a brain-penetrant anaplastic lymphoma kinase (ALK)-selective inhibitor; NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor. Its lead candidates treat solid tumors, non-small cell lung cancer (NSCLC) and brain metastases. The company works in collaboration with contract research organizations (CROs), medical institutions and contract manufacturing organizations (CMOs) to conduct and support preclinical studies and clinical trials. Nuvalent is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of NVL-655’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
